[Peripheral blood stem cell transplantation: current status and perspectives].
Peripheral blood stem cell (PBSC) transplantation is now widely used as technics of stem cell transplantation. If it is efficacious in terms of short-term engraftment, many questions remain unanswered: which is the best technic of mobilization, what role for growth factors after graft, which benefit to add bone marrow stem cells? So, comparative trials are necessary to compare bone marrow transplantation and peripheral stem cell transplantation in terms of long-term engraftment and anti-tumoral effect. However, the present main point is to better define the adequate estimation of circulating hematopoietic progenitors according to the technics of collection: evaluation of CFU-GM and CD34+ levels are inadequate for estimation of immature progenitor cells which vary a lot according to the types of chemotherapy or of growth factors used for mobilization.
Colombat
P
P
Service d'oncologie médicale, CHU Bretonneau, Tours, France.
D015703:Antigens, CD / Q000032:analysis; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation / Q000191:economics / Q000379:methods*; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D011379:Prognosis; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D015703:Antigens, CD; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor